Skip to main content
    A

    AstraZeneca PLC (AZN)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $184.45
    +0.07 (+0.04%)

    Market Cap: $286.07B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    AstraZeneca PLC (AZN) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    AstraZeneca (AZN) trades at 22.5x trailing earnings and 4.6x sales. Its P/E of 22.5x is below its 5-year median of 37.6x. Its forward P/E is 16.3x. The median P/E across 9 similar companies is 19.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 38.0% higher over the next year. Its free cash flow yield is 3.2%.

    MultipleValue
    P/E (trailing)22.5x
    Forward P/E16.3x
    Price to sales4.6x
    Price to book5.6x
    EV/EBITDA14.6x
    Price to FCF30.9x
    EV/FCF33.4x
    PEG1.3
    FCF yield3.2%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/E is 43.3% below 39.7x, its P/S is 9.5% above 4.2x and its P/B is 5.1% below 5.9x.

    MultipleCurrent5-year median10-year median
    P/E22.5x37.6x39.7x
    P/S4.6x4.3x4.2x
    P/B5.6x5.5x5.9x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/E ranged from 25.2x in 2016 to 64.0x in 2019.

    Year endPriceP/EP/SP/B
    2025$183.8630.9x4.9x5.9x
    2024$131.0431.9x3.8x5.0x
    2023$134.7037.0x4.6x5.4x
    2022$135.6040.6x3.2x5.7x
    2021$116.5044.0x3.4x2.3x
    2020$99.9848.1x4.9x8.4x
    2019$99.7264.0x3.6x10.0x
    2018$75.9642.3x4.4x7.7x
    2017$69.4032.3x3.9x5.9x
    2016$54.6425.2x3.0x4.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About AZN

    What is AZN's forward P/E ratio?

    AstraZeneca has a forward P/E ratio of 16.3x.

    Is AZN stock overvalued?

    GNG's valuation label for AZN is Undervalued. Its P/E of 22.5x compares with a median of 19.9x across 9 similar companies.

    What is AZN's price to sales ratio?

    AstraZeneca has a price to sales ratio of 4.6x.

    What is AstraZeneca's average P/E ratio over 5 years?

    AstraZeneca's median P/E over the last 5 years is 37.6x, from 60 month-end values through Oct 2026.

    What is AZN's PEG ratio?

    AstraZeneca has a PEG ratio of 1.3.